Our Management Team
Dr Paul Liknaitzky
Paul Liknaitzky is the Executive Officer of Mind Medicine Australia. He also holds Research Fellow appointments at Deakin University and Odyssey House Victoria. Paul has an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. He has worked on mechanistic experimentation and intervention development within depression and addiction research. Central to Paul’s interests are the clinical benefits and therapeutic mechanisms of psychedelic-assisted treatments. Paul has extensive knowledge of psychedelic research and therapy. He is focused on educating key stakeholders and the general public on medicinal psilocybin and MDMA research for mental illness, and guiding the development and investigation of best-practice clinical protocols that optimize safety, effectiveness, and sustained positive outcomes.
Melissa is a scientist, futurist, science communicator, visual and performance artist. Melissa is a graduate of Neuroscience at the University of Melbourne. Melissa is a member of the management committee of Psychedelic Research in Science & Medicine (PRISM) and co-founder of The Australian Psychedelic Society (APS). In 2016, Melissa was co-organiser of The Multidisciplinary Association for Psychedelic Studies (MAPS) most successful ‘Global Fundraiser’, held at The University of Melbourne. In 2018, Melissa was nominated for as an Innovator by VESKI at FastSmarts during Melbourne Knowledge Week. In her role as Education Officer of Mind Medicine Australia, Melissa uses her vision, tenacity, and rational eye to increase awareness of the clinical potential of psychedelic-assisted therapies.
Dr Martin Williams
Martin Williams, a postdoctoral fellow in Medicinal Chemistry at Monash University, is founding Vice President of Entheogenesis Australia and founding President of Psychedelic Research in Science & Medicine (PRISM). He is also affiliated with Harm Reduction Victoria as a Peer Educator at events and festivals in Victoria. In these various roles, Dr Williams advocates a mature, open discussion about the use of psychoactive plants and chemicals in societies, past and present, and their (increasingly demonstrated) potential to contribute to a more healthy and harmonious future for humanity. With his fellow members of PRISM, he is working to initiate an Australian contribution to the expanding global field of psychedelic medical research. In partnership with St Vincent’s Hospital, PRISM will conduct the first Australian medical trial using psilocybin to ease anxiety and depression for terminally ill patients, supported by Mind Medicine Australia and the Vasudhara Foundation.